ERBB2 and metastatic neoplasm: performed a retrospective analysis on 107 CTC-positive (≥5 CTCs/7.5 mL of blood) samples from MBC patients observing an overall HER2 expression concordance between CTCs and primary and metastatic tumor tissue of 69% and 74%, respectively [27].